-$0.34 EPS Expected for Xencor, Inc. (XNCR) This Quarter
Analysts expect Xencor, Inc. (NASDAQ:XNCR) to post ($0.34) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Xencor’s earnings. The highest EPS estimate is ($0.25) and the lowest is ($0.49). Xencor reported earnings of ($0.21) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 61.9%. The company is expected to announce its next quarterly earnings results on Tuesday, February 27th.
On average, analysts expect that Xencor will report full-year earnings of ($1.15) per share for the current year, with EPS estimates ranging from ($1.29) to ($1.04). For the next fiscal year, analysts anticipate that the business will post earnings of ($1.67) per share, with EPS estimates ranging from ($2.12) to ($1.15). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that follow Xencor.
A number of equities research analysts recently issued reports on the company. BidaskClub raised Xencor from a “strong sell” rating to a “sell” rating in a research report on Thursday, December 7th. Zacks Investment Research raised Xencor from a “sell” rating to a “hold” rating in a research report on Wednesday, November 22nd. ValuEngine raised Xencor from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Piper Jaffray Companies reaffirmed a “buy” rating and set a $35.00 price target on shares of Xencor in a research report on Sunday, November 12th. Finally, Canaccord Genuity set a $36.00 price target on Xencor and gave the stock a “buy” rating in a research report on Monday, October 23rd. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company’s stock. Xencor presently has an average rating of “Hold” and an average price target of $30.80.
In other Xencor news, major shareholder John S. Stafford III bought 3,400 shares of Xencor stock in a transaction dated Wednesday, November 8th. The stock was bought at an average cost of $19.89 per share, for a total transaction of $67,626.00. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder John S. Stafford III bought 9,215 shares of Xencor stock in a transaction dated Thursday, December 14th. The shares were acquired at an average price of $20.76 per share, with a total value of $191,303.40. The disclosure for this purchase can be found here. Insiders have acquired a total of 278,535 shares of company stock worth $5,526,936 in the last ninety days. Insiders own 4.03% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of XNCR. Dimensional Fund Advisors LP boosted its stake in Xencor by 57.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 286,894 shares of the biopharmaceutical company’s stock valued at $6,863,000 after purchasing an additional 104,638 shares during the period. Renaissance Technologies LLC bought a new stake in Xencor in the 1st quarter valued at $949,000. Bank of America Corp DE boosted its stake in Xencor by 144.4% in the 1st quarter. Bank of America Corp DE now owns 16,199 shares of the biopharmaceutical company’s stock valued at $387,000 after purchasing an additional 9,572 shares during the period. Strs Ohio boosted its stake in Xencor by 4.9% in the 2nd quarter. Strs Ohio now owns 36,200 shares of the biopharmaceutical company’s stock valued at $764,000 after purchasing an additional 1,700 shares during the period. Finally, TD Asset Management Inc. boosted its stake in Xencor by 9.3% in the 2nd quarter. TD Asset Management Inc. now owns 81,769 shares of the biopharmaceutical company’s stock valued at $1,726,000 after purchasing an additional 6,963 shares during the period. Institutional investors own 77.62% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “-$0.34 EPS Expected for Xencor, Inc. (XNCR) This Quarter” was first posted by Watch List News and is owned by of Watch List News. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.watchlistnews.com/0-34-eps-expected-for-xencor-inc-xncr-this-quarter/1772007.html.
Xencor Company Profile
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.